Nilotinib induces autophagy in hepatocellular carcinoma through AMPK activation

89Citations
Citations of this article
56Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Nilotinib, an approved drug for leukemia, has been investigated in HCC. Results: Nilotinib induced autophagy in HCC cell lines, including PLC5, Huh-7, and Hep3B. Conclusion: Nilotinib-induced AMPK activation and subsequent autophagy is a major mode of action of nilotinib in HCC. Significance: Elucidating the mechanisms by which nilotinib works on HCC is fundamental to develop the new treatment for HCC. © 2013 by The American Society.

Cite

CITATION STYLE

APA

Yu, H. C., Lin, C. S., Tai, W. T., Liu, C. Y., Shiau, C. W., & Chen, K. F. (2013). Nilotinib induces autophagy in hepatocellular carcinoma through AMPK activation. Journal of Biological Chemistry, 288(25), 18249–18259. https://doi.org/10.1074/jbc.M112.446385

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free